BREAST CANCER RETREAT
Monday, March 11, 2013
George S. Dively Building
Room 202
8:00 AM – 5:30 PM

7:30 – 8:00 AM  REGISTRATION AND BREAKFAST
8:00 – 8:05  WELCOME
8:05 – 8:10  RETREAT INTRODUCTION & OVERVIEW

8:10 – 9:40  SESSION I: Imaging and Nanomedicine
8:10 – 8:30  PET imaging and breast cancer
             Norbert Avril
8:30 – 8:50  Polyhydroxyl fullerenes as a platform for image guided
cancer therapy
             Vijay Krishna
8:50 –9:10  Computerized image based predictors of disease
             aggressiveness: Use cases in breast cancer?
             Anant Madabhushi
9:10 – 9:30  Detection and treatment of breast cancer metastasis using
             nanochains
             Efstathios Karathanasis
9:30 – 9:40  Session Discussion

9:40 – 9:50  BREAK

9:50 – 11:40  SESSION II: Therapy and Drug Resistance
9:50 – 10:10  Novel markers of taxane resistance in breast cancer and
              their potential for use in directing therapy
              George Stark
10:10-10:30  Genomic predictors of response to therapy
              Lyndsay Harris/Tom Budd
10:30-10:50  Runx1 in breast cancer, lessons for novel, non-cytotoxic, p53-independent therapy
*Yogen Saunthararajah*

10:50-11:10  Epigenetic modulation to overcome breast cancer drug resistance
*Vinod Labhasetwar*

11:10-11:30  Identifying new targets for breast cancer immunotherapy
*Greg Plautz*

11:30-11:40  Session Discussion

**11:40 – 12:00 PM**  BREAK/PICK UP BOX LUNCHES

**12:00 – 1:00**  KEYNOTE ADDRESS & LUNCH

TGF-β in breast cancer bone metastases
*Theresa Guise*
Jerry W. and Peggy S. Throgmartin Professor of Oncology
Professor of Medicine, Indiana University School of Medicine

**1:00 – 2:50**  SESSION III: Stem Cells and Metastasis

1:00 – 1:20  The role of the pro-survival protein FIP200 in metastatic breast cancer to the brain
*Candece Gladson*

1:20 – 1:40  Targeting breast cancer stem cell plasticity
*Mark Jackson*

1:40 – 2:00  Autocrine leptin-leptin receptor signaling is necessary for breast cancer stem cell survival and tumorigenicity
*Ofer Reizes*

2:00 – 2:20  A novel model of MEC transformation and metastatic progression: Role of transient EMT: MET programs
*Bill Schiemann*

2:20 – 2:40  Critical roles for Myosin II motor proteins during EMT and invasive cell migration
*Tom Egelhoff*

2:40 – 2:50  Session Discussion

**2:50 – 3:00**  BREAK
3:00 – 4:10  SESSION III: Nuclear Receptors

3:00 – 3:20  Targeting SERM resistant breast cancer
Monica Montano

3:20 – 3:40  TBD
Noa Noy

3:40 – 4:00  FOXA1: Beyond licensing estrogen receptor
Ruth Keri

4:00 – 4:10  Session Discussion

4:10 – 5:00  SESSION IV Genetics and Prevention

4:10 – 4:30  Cleveland Clinic’s PTEN research studies: Breast cancer and beyond
Jessica Mester

4:30 – 4:50  Breast cancer studies in cancer prevention and control at Case
Susan Flocke

4:50 – 5:00  Session Discussion

5:00 – 5:30  PROGRAMMATIC DISCUSSION & CONCLUSIONS